Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Dexcom, Inc. reported the results of its 2026 Annual Meeting of Stockholders. At the record date, there were 385,872,977 shares of common stock outstanding and entitled to vote, and 336,525,352 shares were present in person or by proxy, establishing a quorum.
Stockholders elected twelve directors to serve until the 2027 annual meeting or earlier departure. They also ratified Deloitte & Touche LLP as Dexcom’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 336,046,596 votes for and 373,544 against. In addition, stockholders approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers, with 277,111,475 votes for and 36,664,959 against.
Dexcom Inc. President, CEO, and Director Jacob Steven Leach reported a tax-related share withholding and updated holdings. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations tied to net settlement of restricted stock units, and a footnote states this does not represent a sale by him.
After this withholding, Leach directly owned 420,359 Dexcom shares. A separate entry shows 47,296 shares held indirectly as family holdings through the Gregg Family Grandchildren's Trust, where his spouse serves as a trustee. Footnotes also note 145,686 unvested restricted stock units scheduled to vest between March 8, 2027 and March 8, 2029.
Dexcom executive Michael Jon Brown reported a routine tax-related share withholding tied to restricted stock units. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations from the net settlement of vested RSUs, and the footnote clarifies this was not an open-market sale.
After the withholding, Brown directly holds 108,053 Dexcom shares, which include 74,753 unvested restricted stock units scheduled to vest in tranches through March 8, 2029.
Dexcom EVP and Chief Financial Officer Sylvain Jereme M reported a routine tax-related share withholding. On May 22, 2026, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations tied to restricted stock unit settlement, and the footnote clarifies this does not represent a sale.
After this withholding, he directly holds 151,841 shares of common stock, which includes 89,944 unvested restricted stock units. These RSUs were granted in multiple awards between March 8, 2024 and March 8, 2026 and are scheduled to vest through March 8, 2029, indicating a significant ongoing equity-based compensation position.
Dexcom EVP Chief People & Culture Officer Sadie Stern reported a routine tax-withholding event related to equity compensation. On the reported date, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations from the net settlement of restricted stock units.
The footnotes clarify this was not an open-market sale, but shares retained by the company to satisfy required tax withholding and remittance. After this withholding, Stern directly held 130,059 Dexcom shares, including 74,753 unvested restricted stock units that vest on various schedules through March 8, 2029.
Dexcom EVP Jon Coleman had shares withheld to cover taxes on stock awards. On this Form 4, 7,362 shares of Dexcom common stock were surrendered at $71.90 per share to satisfy tax withholding obligations from the net settlement of restricted stock units, and this is explicitly stated not to be a sale.
After this tax withholding, Coleman directly holds 105,273 shares of Dexcom, including 95,450 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029 and May 22, 2029. This filing reflects routine compensation-related tax treatment rather than an open‑market trade.
Dexcom Executive Chair Kevin R. Sayer reported an open-market sale of 26,759 shares of Dexcom common stock on May 21, 2026 at $72.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2026, which is designed to allow the orderly disposition of his shares over time.
Following this sale, Sayer directly owns 382,482 Dexcom shares, which include 106,972 unvested restricted stock units. These unvested units stem from grants made on March 8, 2024, 2025, and 2026, each scheduled to vest gradually through dates between 2027 and 2028.
Dexcom Inc. executive vice president and chief legal officer Michael Jon Brown sold 1,700 shares of common stock on May 15, 2026 in an open-market trade at $59.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025. After the transaction, he holds 109,504 shares directly, including 77,603 unvested RSUs that are scheduled to vest in tranches through March 8, 2029.
Michael Brown reported securities sales and a planned restricted-stock sale. The filing lists sales of 1,700 shares of Common Stock on 04/15/2026 for $107,168.00 and 1,700 shares on 03/16/2026 for $110,245.00. The form also shows 1,700 restricted shares referenced with a 03/08/2026 trade date and Morgan Stanley Smith Barney LLC as the broker.